Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

PHILADELPHIA PA Marketwired 030917 Aevi Genomic Medicine Inc. NASDAQ GNMX Topline data from SAGA Phase 23 trial of AEVI001 in adolescents with mGluR ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI001 signal finding studies...